Peptides: What They Are and Why Everyone Is Talking About Them
You’ve heard of Ozempic. You’ve heard of Mounjaro. Maybe you’ve heard of BPC-157 from the fitness world.
These are all peptides. And right now, peptides are the fastest-growing category in health optimization.
But most people are confused about what they actually are, what they do, and which ones matter. Let’s fix that.
What are peptides?
Peptides are short chains of amino acids — the building blocks of proteins. Your body already makes thousands of them. They act as signaling molecules, telling your cells what to do.
Think of peptides as text messages between cells. Insulin is a peptide. Collagen is a peptide. The hormone that tells your body to burn fat or heal a wound — peptide.
When people talk about “taking peptides,” they mean supplementing with specific peptide sequences to trigger specific biological responses. Weight loss. Healing. Anti-aging. Muscle growth. Brain function.
Why everyone is talking about them now
Three reasons:
1. Ozempic changed everything. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist peptide. It generated $14 billion in revenue in 2024 alone. It proved that peptides work for mainstream health conditions — not just niche biohacking.
2. The research exploded. A 2025 systematic review in Annals of Internal Medicine confirmed that GLP-1 receptor agonists produce significant weight loss in adults without diabetes (Moiz et al., 2025). A 2025 review in Pharmacological Reviews catalogued emerging peptide therapies for obesity, including retatrutide — a triple-agonist peptide that may outperform everything on the market (Kokkorakis et al., 2025).
3. Access expanded. Compounded versions, research peptides, and telehealth clinics made peptides available outside traditional medicine. Whether that’s good or bad depends on who you ask — but it’s the reality.
The peptides that matter
For weight loss
Semaglutide (Ozempic, Wegovy)
- What it does: mimics GLP-1 hormone, reduces appetite, slows gastric emptying
- Results: 15-20% body weight loss in clinical trials
- Status: FDA-approved for weight loss (Wegovy) and diabetes (Ozempic)
Tirzepatide (Mounjaro, Zepbound)
- What it does: dual GLP-1 + GIP agonist — hits two pathways instead of one
- Results: up to 22.5% body weight loss in trials
- Status: FDA-approved
Retatrutide (not yet approved)
- What it does: triple agonist — GLP-1 + GIP + glucagon
- Results: up to 24% weight loss in phase 2 trials
- Status: phase 3 trials ongoing, expected approval 2026-2027
- Why it matters: A 2025 review in Biomolecules called it “a game changer in obesity pharmacotherapy” (Katsi et al., 2025)
For gut healing and inflammation
BPC-157 (Body Protection Compound)
- What it does: promotes gut lining repair, reduces inflammation, accelerates wound healing
- Where it shines: gut issues (IBS, leaky gut), tendon/ligament injuries, joint pain
- Status: not FDA-approved, available as research peptide
- Research: animal studies show strong gut-protective and anti-inflammatory effects; human trials are limited
For muscle recovery
TB-500 (Thymosin Beta-4)
- What it does: promotes cell migration, wound healing, and tissue repair
- Where it shines: muscle tears, post-surgery recovery, chronic inflammation
- Status: research peptide, not FDA-approved
For anti-aging and growth hormone
CJC-1295 / Ipamorelin
- What it does: stimulates natural growth hormone release
- Where it shines: sleep quality, recovery, body composition, skin quality
- Status: research peptide, not FDA-approved
- Note: growth hormone declines 15% per decade after 30. These peptides aim to restore it.
For skin
GHK-Cu (Copper peptide)
- What it does: stimulates collagen production, wound healing, skin remodeling
- Where it shines: anti-aging, skin firmness, hair growth
- Status: available in skincare products (cosmetic grade)
The honest picture
What’s proven:
- Semaglutide and tirzepatide for weight loss — massive clinical trial data
- GLP-1 peptides for metabolic health — well-established
What’s promising but early:
- BPC-157 for gut healing — strong animal data, limited human trials
- CJC-1295/Ipamorelin for growth hormone — shows effects, needs more research
- Retatrutide — phase 2 results are exceptional, waiting on phase 3
What’s mostly hype:
- “Anti-aging peptide stacks” sold by random websites
- Peptide combinations with no clinical data
- Anything marketed as “miracle” or “breakthrough” without reference to specific studies
Where to learn more
The QI peptide series continues with deep dives:
- Semaglutide vs Tirzepatide: Which weight loss peptide is actually better (coming May 14)
- BPC-157: The gut healing peptide your doctor won’t mention (coming May 16)
- Peptides for women over 40: Anti-aging, hormones, and fat loss (coming May 18)
- Retatrutide: The next weight loss peptide everyone is waiting for (coming May 20)
- GHK-Cu: The skin peptide that actually works (coming May 22)
The bottom line
Peptides aren’t magic. They’re biology. Specific molecules triggering specific responses in your body. Some have massive clinical trial support (semaglutide, tirzepatide). Some have promising data but need more research (BPC-157, CJC-1295). Some are mostly marketing.
The key is knowing which is which. That’s what this series is for.
This post is for educational purposes only. It is not medical advice. Peptides discussed are not all FDA-approved for the uses described. Always consult your doctor before starting any peptide protocol.
References:
Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss. Moiz A et al., Ann Intern Med (2025). PubMed
Emerging pharmacotherapies for obesity: A systematic review. Kokkorakis M et al., Pharmacol Rev (2025). PubMed
Retatrutide — A Game Changer in Obesity Pharmacotherapy. Katsi V et al., Biomolecules (2025). PubMed
What is the pipeline for future medications for obesity? Melson E et al., Int J Obes (2025). PubMed
Compounded GLP-1 receptor agonists for weight loss. DiStefano MJ et al., J Pharm Policy Pract (2025). PubMed